Equities

Avanos Medical Inc

Avanos Medical Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)18.63
  • Today's Change0.61 / 3.39%
  • Shares traded149.83k
  • 1 Year change-12.70%
  • Beta0.9453
Data delayed at least 15 minutes, as of Nov 22 2024 19:23 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform1
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Avanos Medical Inc have a median target of 22.50, with a high estimate of 25.00 and a low estimate of 20.00. The median estimate represents a 24.86% increase from the last price of 18.02.
High38.7%25.00
Med24.9%22.50
Low11.0%20.00

Earnings history & estimates in USD

On Oct 30, 2024, Avanos Medical Inc reported 3rd quarter 2024 earnings of 0.36 per share. This result was in line with the consensus of the 3 analysts following the company and under-performed last year's 3rd quarter results by 14.29%.
The next earnings announcement is expected on Feb 18, 2025.
Average growth rate+1.34%
Avanos Medical Inc reported annual 2023 earnings of 1.38 per share on Feb 20, 2024.
Average growth rate+11.63%
More ▼

Revenue history & estimates in USD

Avanos Medical, Inc. had 3rd quarter 2024 revenues of 170.40m. This missed the 175.33m consensus estimate of the 3 analysts following the company. This was 6.97% above the prior year's 3rd quarter results.
Average growth rate-0.09%
Avanos Medical, Inc. had revenues for the full year 2023 of 673.30m. This was 17.89% below the prior year's results.
Average growth rate-0.28%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.